Fentanyl increases dopamine release in rat nucleus accumbens: Involvement of mesolimbic MU- and delta-2-opioid receptors

Neuroscience

Volumn 92, Issue 4, 1999, Pages 1357-1365

  Yoshida, Y ^a   Koide, S ^a   Hirose, N ^a   Takada, K ^a   Tomiyama, K ^a   Koshikawa, N ^a   Cools, A R ^b  

^a NIHON UNIVERSITY   (Japan)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

1 opioid receptor; 2 opioid receptor; opioid receptor; Dopamine release; Fentanyl; Nucleus accumbens

Indexed keywords

7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; FENTANYL; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTRIBEN; NALTRINDOLE; OPIATE ANTAGONIST;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC CORTEX; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; INJECTIONS, INTRAVENOUS; LIMBIC SYSTEM; MALE; MICRODIALYSIS; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 0033011195     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00046-9     Document Type: Article

References (59)

1. Abdelhamid E.E., Sultana M., Portoghese P.S., Takemori A.E. Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmac. exp. Ther. 258:1991;299-303.
2. Benveniste H., Hansen A.J., Ottosen N.S. Determination of brain interstitial concentration by microdialysis. J. Neurochem. 52:1989;1741-1750.
3. Benveniste H., Hüttemeier P.C. Microdialysis - theory and application. Prog. Neurobiol. 35:1990;195-215.
4. Borg P.J., Taylor D.A. Involvement of μ- and δ-opioid receptors in the effects of systemic and locally perfused morphine on extracellular levels of dopamine, DOPAC and HVA in the nucleus accumbens of the halothane-anaesthetized rat. Naunyn-Schmiedeberg's Arch. Pharmac. 355:1997;582-588.
5. Broekkamp C.L.E., Phillips A.G., Cools A.R. Stimulant effects of enkephalin microinjection into the dopaminergic A10 area. Nature. 278:1979;560-562.
6. Cador M., Rivet J.-M., Kelley A.E., Le Moal M., Stinus L. Substance P, neurotensin and enkephalin injections into the ventral tegmental area: comparative study on dopamine turnover in several forebrain structures. Brain Res. 486:1989;357-363.
7. Daugé V., Kalivas P.W., Duffy T., Roques B.P. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. Brain Res. 599:1992;209-214.
8. Devine D.P., Leone P., Pocock D., Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmac. exp. Ther. 226:1993;1236-1246.
9. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. natn. Acad. Sci. U.S.A. 85:1988;5274-5278.
10. Di Chiara G., Imperato A. Opposite effects of mu and kappa opioid agonists on dopamine release in the nucleus accumbens and dorsal caudate of freely moving rats. J. Pharmac. exp. Ther. 244:1988;1067-1080.
11. Erspamer V., Melchiorri P., Falconieri-Erspamer G., Negri L., Corsi R., Severini C., Barra D., Simmaco M., Kreil G. Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for δ opioid binding sites. Proc. natn. Acad. Sci. U.S.A. 86:1989;5188-5192.
12. Fibiger H.L. Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. A. Rev. Pharmac. Toxicol. 18:1982;37-52.
13. Goldstein A., Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Molec. Pharmac. 36:1989;265-272.
14. Hakan R.L., Henriksen S.J. Opiate influences on nucleus accumbens neuronal electrophysiology: dopamine and non-dopamine mechanisms. J. Neurosci. 9:1989;3538-3546.
15. Handa B.K., Lane A.C., Lord J.A.H., Morgan B.A., Rance M.J., Smith C.F.C. Analogues of β-LPH61-64 possessing selective agonist activity at μ-opiate receptors. Eur. J. Pharmac. 70:1981;531-540.
16. Hruby V.J., Gehrig C.A. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 9:1989;343-401.
17. Johnson D.W., Glick S.D. Dopamine release and metabolism in nucleus accumbens and striatum of morphine-tolerant and nontolerant rats. Pharmac. Biochem. Behav. 46:1993;341-347.
18. Kalivas P.W., Wilderlow E., Stanley D., Breese G., Prange A.J. Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmac. exp. Ther. 227:1983;229-237.
19. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
20. Kosterlitz H.W. The Wellcome Foundation Lecture, 1982. Opioid peptides and their receptors. Proc. R. Soc. Lond. 225:1985;27-40.
21. Kramer T.H., Shook J.E., Kazmierski W., Ayres E.A., Wire W.S., Hruby V.J., Burks T.F. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmac. exp. Ther. 249:1989;544-551.
22. Kreil G., Barra D., Simmaco M., Erspamer V., Erspamer G.F., Negri L., Severini C., Corsi R., Melchiorri P. Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for delta opioid receptors. Eur. J. Pharmac. 162:1989;123-128.
23. Latimer L.G., Duffy P., Kalivas P.W. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J. Pharmac. exp. Ther. 241:1987;328-337.
24. Lee P.H., McNutt R.W., Chang K.-J. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J. Pharmac. exp. Ther. 267:1993;883-887.
25. Leone P., Pocock D., Wise R.A. Morphine-dopamine interaction: ventral tegmental morphine increase nucleus accumbens dopamine release. Pharmac. Biochem. Behav. 39:1991;469-472.
26. Lindefors N., Amberg G., Ungerstedt U. Intracerebral microdialysis, I. Experimental studies of diffusion kinetics. J. pharmac. Meth. 22:1989;141-156.
27. 1-dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J. Neurosci. 11:1991;1565-1576.
28. Maguire P., Tsai N., Kamal J., Cometta-Morini C., Upton C., Loew G. Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur. J. Pharmac. 231:1992;219-225.
29. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent and morphine: an in vivo microdialysis study. Eur. J. Pharmac. 199:1991;35-42.
30. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7:1987;2445-2464.
31. Mosberg H.L., Hurst R., Hruby V.J., Yamamura H.I., Galligan J.J., Burks T.F. Bis-penicillamine enkephalins possess highly improved specificity towards opioid receptors. Proc. natn. Acad. Sci. U.S.A. 80:1983;5871-5874.
32. Murai T., Koshikawa N., Kanayama T., Takada K., Tomiyama K., Kobayashi M. Opposite effects of midazolam and β-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur. J. Pharmac. 261:1994;65-71.
33. Narita M., Suzuki T., Funada M., Misawa M., Nagase H. Involvement of δ-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice. Psychopharmacology, Berlin. 111:1993;423-426.
34. Nestler E.J. Molecular mechanisms of drug addiction. J. Neurosci. 12:1992;2439-2450.
35. O'Neill S.T., Collins M.A., Pettit H.O., McNutt R.W., Chang K.-J. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J. Pharmac. exp. Ther. 282:1997;271-277.
36. Parry T.J., Carter T.L., McElligott J.G. Physical and chemical considerations in the in vitro calibration of microdialysis probes for biogenic amine neurotransmitters and metabolites. J. Neurosci. Meth. 323:1990;175-183.
37. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
38. Pelton J.T., Kazmierski W., Gulya K., Yamamura H.I., Hruby V.J. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ opioid receptors. J. med. Chem. 29:1986;2370-2375.
39. Pentney R.J.W., Gratton A. Effects of local delta and mu opioid receptor activation on basal and stimulated dopamine release in striatum and nucleus accumbens of rat: an in vivo electrochemical study. Neuroscience. 45:1991;95-102.
40. Petit F., Hamon M., Fournie-Zaluski M.C., Roques B.P., Glowinski J. Further evidence for a role of δ-opiate receptors in the presynaptic regulation of newly synthesized dopamine release. Eur. J. Pharmac. 126:1986;1-9.
41. Portoghese P.S. An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: δ opioid antagonists. J. med. Chem. 346:1991;1757-1762.
42. Portoghese P.S., Nagase H., MaloneyHuss K.E., Lin C.E., Takemori A.E. Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J. med. Chem. 34:1991;1715-1720.
43. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur. J. Pharmac. 218:1992;195-196.
44. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur. J. Pharmac. 146:1988;185-186.
45. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
46. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396:1986;157-198.
47. Rothman R.B., Westfall T.C. Allosteric coupling between morphine and enkephalin receptors in vitro. Molec. Pharmac. 21:1982;538-557.
48. Sharif N.A., Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides. 10:1989;499-522.
49. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. natn. Acad. Sci. U.S.A. 89:1992;2046-2050.
50. Suzuki T., Yoshiike M., Mizoguchi H., Kamei J., Misawa M., Nagase H. Blockade of δ-opioid receptors prevents morphine-induced place preference in mice. Jpn. J. Pharmac. 66:1994;131-137.
51. Takada K., Murai T., Kanayama T., Koshikawa N. Effects of midazolam and flunitrazepam on the release of dopamine from rat striatum measured by in vivo microdialysis. Br. J. Anaesth. 70:1993;181-185.
52. Tomiyama K., Koshikawa N., Funada K., Oka K., Kobayashi M. In vivo microdialysis evidence for transient dopamine release by benzazepines in rat striatum. J. Neurochem. 65:1995;2790-2795.
53. Tomiyama K., Noguchi M., Koshikawa N., Kobayashi M. YM-09151-2 but not L-sulpiride induces transient dopamine release in rat striatum via a tetrodotoxin-insensitive mechanism. J. Neurochem. 60:1993;1690-1695.
54. Vaught J.L., Takemori A.E. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J. Pharmac. exp. Ther. 208:1979;86-90.
55. Wise R.A. Catecholamine theories of reward: a critical review. Brain Res. 152:1978;215-247.
56. Wise R.A., Rompré P.P. Brain dopamine and reward. A. Rev. Psychol. 40:1989;191-225.
57. Wood P., Richard J.W. Morphine and nigrostriatal function in rat and mouse: the role of nigral and striatal opiate receptors. Neuropharmacology. 21:1982;1305-1320.
58. Yeadon M., Kitchen I. Comparative binding of μ and δ selective ligands in whole brain and pons/medulla homogenates from rat: affinity profiles of fentanyl derivatives. Neuropharmacology. 27:1988;345-348.
59. Yoshida M., Yokoo H., Tanaka T., Mizoguchi K., Emoto H., Ishii H., Tanaka M. Facilitatory modulation of mesolimbic dopamine neuronal activity by a μ-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 624:1993;277-280.